Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II alpha/beta T-/CD19 B-cell depleted allo-SCT with innate donor lymphocyte infusion in high-risk or relapsed acute leukemia/MDS
2010-021221-12Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in Acute Leukaemia, myelodysplastic syndrome (MDS) and hematopoietic malignancies, sponsored by University Medical Center Utrecht. Primary endpoints: Feasibility and safety of alpha/beta T-/CD19 B-cell depleted allo-SCT followed by innate donor lymphocyte infusion and Immune reconstitution parameters. Started Oct 2010; status: active.
02
Drugs
zoledronic acid
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)hematopoietic malignancies
Beyond the preview
Go deeper on 2010-021221-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021221-12.